Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-OLE: AOC 1020 in Facioscapulohumeral Muscular Dystrophy
NCT06547216Phase 2Active, not recruiting
- Sponsor
- Avidity Biosciences
- Start
- Jul 2024
- Primary completion
- Apr 2030
- Modality
- Antisense DNA, Antibody-Drug Conjugates (ADCs), Conjugated siRNA
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of delpacibart braxlosiran in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Avidity Biosciences. Primary endpoint: Incidence of treatment-emergent adverse events at Day 729. Started Jul 2024; status: active, not recruiting.
02
Drugs
delpacibart braxlosiran
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT06547216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547216.